Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.4 million.

  • Phathom Pharmaceuticals' Net Cash Flow fell 12466.29% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.5 million, marking a year-over-year decrease of 26488.74%. This contributed to the annual value of -$84.1 million for FY2024, which is 13684.04% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Net Cash Flow of -$14.4 million as of Q3 2025, which was down 12466.29% from -$62.7 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Net Cash Flow peaked at $167.7 million during Q4 2023, and registered a low of -$84.9 million during Q1 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Net Cash Flow value was -$32.8 million (recorded in 2023), while the average stood at -$9.4 million.
  • Data for Phathom Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 55630.35% (in 2023) and a maximum YoY decrease of 21116.16% (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Net Cash Flow stood at -$41.5 million in 2022, then surged by 504.61% to $167.7 million in 2023, then crashed by 122.31% to -$37.4 million in 2024, then surged by 61.48% to -$14.4 million in 2025.
  • Its Net Cash Flow was -$14.4 million in Q3 2025, compared to -$62.7 million in Q2 2025 and -$84.9 million in Q1 2025.